Maria Assunta Rotundo
YOU?
Author Swipe
View article: Cost-utility analysis of evolocumab in patients with ASCVD in Italy
Cost-utility analysis of evolocumab in patients with ASCVD in Italy Open
Objective: The aim of this work was to evaluate the cost-effectiveness of evolocumab in addition to standard statin therapy with or without ezetimibe in the treatment of patients with clinically evident atherosclerotic cardiovascular disea…
View article: Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia Open
Introduction: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibioti…
View article: Osteoporosis: Economic Burden of Disease in Italy
Osteoporosis: Economic Burden of Disease in Italy Open
View article: PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY
PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY Open
View article: PMS19 COST OF ILLNESS OF OSTEOPOROSIS IN ITALY
PMS19 COST OF ILLNESS OF OSTEOPOROSIS IN ITALY Open
View article: Cost of illness of spinal muscular atrophy (SMA) in Italy
Cost of illness of spinal muscular atrophy (SMA) in Italy Open
The objective of this study was to estimate the indirect and direct non-health costs associated with spinal muscular atrophy (SMA), a disease that burdens the daily life of adults, children and their families in Italy. In order to develop …
View article: The economic impact of biosimilars in Italy: a scenario analysis
The economic impact of biosimilars in Italy: a scenario analysis Open
Background: the first generation of biotechnology drugs is reaching, or has already reached, the patent expiry and a large number of biosimilars is entering the Italian pharmaceutical market. The objective of the analysis was to evaluate t…
View article: Cost of illness of spinal muscular atrophy (SMA) in Italy
Cost of illness of spinal muscular atrophy (SMA) in Italy Open
The objective of this study was to estimate the indirect and direct non-health costs associated with spinal muscular atrophy (SMA), a disease that burdens the daily life of adults, children and their families in Italy. In order to develop …
View article: The economic impact of biosimilars in Italy: a scenario analysis
The economic impact of biosimilars in Italy: a scenario analysis Open
Background: the first generation of biotechnology drugs is reaching, or has already reached, the patent expiry and a large number of biosimilars is entering the Italian pharmaceutical market. The objective of the analysis was to evaluate t…
View article: PSY71 - ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY IN ITALY
PSY71 - ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY IN ITALY Open